Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 2
- Registration Number
- NCT02844582
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 196
- Registration Number
- NCT02703623
- Locations
- 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson in Sugar Land, Sugar Land, Texas, United States
Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Erasmus Medical Center
- Registration Number
- NCT02621190
- Locations
- 🇳🇱
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT02560337
- Locations
- 🇩🇰
Vejle Hospital, Department of Oncology, Vejle, Denmark
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02522715
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Portland VA Medical Center, Portland, Oregon, United States
Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 60
- Registration Number
- NCT02512458
- Locations
- 🇬🇷
EUROMEDICA General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece
🇬🇷Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology, Athens, Greece
🇬🇷Athens Medical Center, Dept of Medical Oncology, Athens, Maroussi, Greece
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 14
- Registration Number
- NCT02478502
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T), Meldola, Italy
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇸🇪University Hospital of Uppsala, Department of Oncology, Uppsala, Sweden
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 120
- Registration Number
- NCT02254785
- Locations
- 🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇨🇦Durham Regional Cancer Centre (Lakeridge Health), Oshawa, Ontario, Canada
Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Hospital Clinico Universitario de Santiago
- Target Recruit Count
- 38
- Registration Number
- NCT02204332
- Locations
- 🇪🇸
Hospital General de Valencia, Valencia, Spain
🇪🇸Hospital Clinico de Santiago, Santiago de Compostela, Spain
🇪🇸Hospital Arnau de Vilanova, Lérida, Spain
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Guarionex J. Decastro
- Target Recruit Count
- 51
- Registration Number
- NCT02202772
- Locations
- 🇺🇸
Columbia University Irving Medical Center - HIP, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.